First Trust Advisors LP Makes New $248,000 Investment in Smith & Nephew plc (NYSE:SNN)

First Trust Advisors LP bought a new stake in shares of Smith & Nephew plc (NYSE:SNNFree Report) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 10,093 shares of the medical equipment provider’s stock, valued at approximately $248,000.

Other institutional investors have also recently modified their holdings of the company. Principal Securities Inc. increased its stake in Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 691 shares during the last quarter. R Squared Ltd bought a new position in shares of Smith & Nephew in the 4th quarter valued at $41,000. National Bank of Canada FI raised its holdings in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 446 shares in the last quarter. Hara Capital LLC lifted its position in shares of Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Smith & Nephew by 31.8% in the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after buying an additional 718 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on SNN. HSBC downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. UBS Group lowered shares of Smith & Nephew from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Canaccord Genuity Group raised their target price on Smith & Nephew from $27.00 to $28.00 and gave the company a “hold” rating in a report on Thursday, May 1st. Finally, Hsbc Global Res downgraded Smith & Nephew from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.00.

View Our Latest Report on SNN

Smith & Nephew Trading Down 0.1 %

NYSE:SNN opened at $28.31 on Friday. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The company has a 50-day moving average price of $27.56 and a 200-day moving average price of $26.27. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock has a market cap of $12.40 billion, a price-to-earnings ratio of 13.11, a P/E/G ratio of 1.26 and a beta of 0.68.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be issued a $0.447 dividend. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. The ex-dividend date is Friday, March 28th. This represents a dividend yield of 2.5%. Smith & Nephew’s dividend payout ratio (DPR) is presently 41.20%.

About Smith & Nephew

(Free Report)

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Featured Articles

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNNFree Report).

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.